Day: January 3, 2024

Noerresundby, Denmark, 3 January 2024Announcement no.01/2024Enclosed please find the notice convening the Annual General Meeting of RTX to be held on Thursday 25 January 2024 at 3.00 pm at the Company’s address: Stroemmen 6, Noerresundby. Best regards,RTX A/S Peter Røpke        CEO Questions and further information: Peter Røpke, CEO, tel. +45 96 32 23 00Please visit RTX’s website at: www.rtx.dkAttachmentRTX CA No 01-2024 – 03.01.24 – Notice of AGM with agenda and complete proposals

First clinical trial to evaluate the safety and efficacy of OBI-992, a novel antibody – drug conjugate (ADC) targeting TROP2. Dosing of first patient in the Phase 1/2 clinical trial expected in early 2024. TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) — OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody – drug conjugate (ADC) cancer therapy targeting TROP2. OBI plans to enroll patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and gastric cancer (GC), although several other cancers are also potential targets. OBI Pharma’s Chief Medical Officer, Wayne Saville,...

Vancouver, B.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — CryptoBlox Technologies Inc. (the “Company” or “CryptoBlox”) (CSE: BLOX) wishes everyone a Happy New Year and is pleased to provide a corporate update summarizing the progress and developments in 2023, which focused on CryptoBlox building its diversified Blockchain Ecosystem Strategy (the “Blockchain Ecosystem Strategy”). This started with the acquisition of Redwater Acquisition Corp. (“Redwater”), a modular air-cooled data center facility, powered by flared gas in Sturgeon County, Alberta. The Company then acquired a royalty-free worldwide technology license from Crypto Green Tech Inc. (“Crypto Green”) to develop and distribute products based on Crypto Green’s crypto-mining hybrid solar and wind technology. Finally, the Company signed an LOI to acquire the rights to a digital asset...

Company Announcement 3 January 2024Announcement No. 2 Notification of major shareholding – correction The information on Morgan Stanley’s shareholding provided in company announcements no. 38 of 22 December 2023 and no. 1 of 2 January 2024 were incorrect. The correct information with reference to Section 30 of the Danish Capital Market Act is that:19 December 2023: Morgan Stanley reduced its total voting rights in NKT attached to shares and through financial instruments from 6.69% to 5.31%. 27 December 2023: Morgan Stanley’s total voting rights in NKT attached to shares and through financial instruments were below the 5% threshold.ContactInvestor Relations:         Michael Nass Nielsen, Head of Investor Relations, Tel: +45 2494 1654Press:                            Louise W. Naldal, Head of Group Communications, Tel: +45 2982...

The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD)Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). “The progress of our product pipeline clearly illustrates the advantage of our integrated development and manufacturing platform, which allows Alvotech to pursue its diversified global biosimilar strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Completing this key clinical milestone for AVT06, also demonstrates how our integrated approach...

The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients with neovascular (wet) Age-related Macular Degeneration (AMD) REYKJAVIK, Iceland, Jan. 03, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). “The progress of our product pipeline clearly illustrates the advantage of our integrated development and manufacturing platform, which allows Alvotech to pursue its diversified global biosimilar strategy,” said Robert Wessman, Chairman and CEO of Alvotech. “Completing this key clinical...

By agreement, Hugo Dorph will leave his position as CCO and member of Solar’s Executive Board today. Hugo Dorph has been member of the Executive Board since 2016 and a key player in the preparation of Solar’s new strategy for the period 2024-26. The new strategy will be launched on 8 February 2024 in connection with the publication of Solar’s Annual Report for 2023. In drawing up the new strategy, it has become clear that the CCO position is no longer required. Chair of Board of Directors Michael Troensegaard Andersen says:“In preparing our new strategy for the period 2024-26, it has become clear that the role as CCO is no longer required to support Solar’s onward journey. Therefore, the Board of Directors has agreed with CCO Hugo Dorph that he will step down from his position today. We would like to thank...

Serstech today received an order of 5.5 MSEK from its partner Safeware in the USA. The order contains Serstech Arx, the patented SERS kit and Serstech ChemDash software. The order will be delivered to Colorado State Patrol and invoiced in the first quarter of 2024.  “Colorado State Patrol is a distinguished law enforcement organization that sets the standard for local law enforcement in the state. We are honored by their trust in Serstech, and we look forward to supporting them in their important work against narcotics”, says Serstech CEO Stefan Sandor. For further information, please contact: Stefan Sandor, CEO, Serstech AB Phone: +46 739 606 067 Email: ss@serstech.com or Thomas Pileby, Chairman of the Board, Serstech AB Phone: +46 702 072 643 Email: tp@serstech.com or visit: www.serstech.com This is information that Serstech AB (publ.)...

Figure 1Location of LIFT’s Yellowknife Lithium Project. Drilling has been thus far focused on the Road Access Group of pegmatites which are located to the east of the city of Yellowknife along a government-maintained paved highway, as well as the Echo target in the Further Afield Group.Figure 2Plan view showing the surface expression of the BIG East pegmatite with diamond drill holes reported in this press release.Figure 3Cross-section illustrating YLP-0117 with results as shown in the BIG East pegmatite dyke with a 26 m interval of 1.56% Li2O.Figure 4Cross-section illustrating YLP-0129 with results as shown in the BIG East pegmatite dyke with an 18 m interval of 0.95% Li2O.Figure 5Plan view showing the surface expression of the Echo pegmatite with diamond drill holes reported in this press...